Immunovant, Inc.
Immunovant, Inc. (IMVT) SEC Filings & 10-K Annual Reports
SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.
SEC EDGAR · data.sec.gov · CIK 0001764013 · IMVT · NASDAQ · as of Jun 8, 2026
Filing snapshot
Source: SEC EDGAR (data.sec.gov) · CIK 0001764013 · Updated hourly · Not investment advice
Latest Annual Report
Latest Key Filings
Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.
SEC Filing History
About SEC Filings & 10-K Annual Reports
Immunovant, Inc. (NASDAQ: IMVT) has submitted 613 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2019. As a Healthcare sector company with CIK 0001764013, all filings are publicly accessible via the EDGAR database at no cost.
The annual 10-K report is Immunovant, Inc.'s most comprehensive regulatory disclosure. The most recent Immunovant, Inc. 10-K was filed on 2026-05-20 for fiscal year ending 2026. Historical IMVT 10-K annual reports are available from 2019 through 2026.
Investors researching Immunovant, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.
Frequently Asked Questions
IMVT SEC Filings · 8 questionsImmunovant, Inc. (IMVT) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 613 filings and access original documents at no cost. Immunovant, Inc.'s CIK is 0001764013.